A study of 11 drugs now in clinical trials suggests they do kill cancer cells—but through a different mechanism than indicated in previous research.

Fly avatars bearing multiple genetic changes akin to those of a cancer patient lead to a tailor-made treatment that has shrunk the patient’s tumors.

The scientist and clinician helped develop a new form of cancer therapy, using a monoclonal antibody to treat head, neck, colorectal, and lung cancers.

Loxo focuses on cancer treatments based on tumor genetics, which will contribute to Lilly’s push in the cancer drug space.

The deal between the two biopharmaceutical giants will boost the purchaser’s cancer drug portfolio.

A case study of two patients with advanced cancer shows it might be possible to avoid a common and severe side effect of immunotherapy treatment.

Researchers use several different strategies to deliver a one-two punch.

Pharmaceutical giant Sanofi to take over hemophilia drugmaker Biovertiv, while Celgene will buy cancer drugmaker Juno Therapeutics.

The pharmaceutical firm beat out a host of potential suitors, Johnson & Johnson among them, to strike a $21 billion deal with Pharmacyclics.